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Introduction 
Effervescent tablets were designed to produce solutions 
that  release  carbon  dioxide  simultaneously.  Usually, 
these  tablets  are  prepared  by  compressing  the  active 
ingredients  with  mixture  of  sodium  bicarbonate  and 
organic acids such as citric and tartaric acid.
1  
Generally,  these  tablets  are  included  drugs  that  are 
solved  rapidly  when  entered  to  water  and  they  are 
recommended  as  a  clear  and  palatable  solution.
2  So, 
they can be prescribed to patients who suffered from 
swallow  capsules  or  tablets.
3The  main  advantages  of 
effervescent  tablets  are  quick  production  of  solution. 
Thus, it is faster and better to absorb.
4  
As a source of acid, citric acid is the most used acid. 
Also other acids such as tartaric, fumaric, adipic, malic 
acid  and  anhydrides  and  salts  of  acid  can  be  used. 
Potassium  and  sodium  carbonate,  sodium  and 
potassium bicarbonate, arginine carbonate are used as a 
sources  of  alkali.  Sodium  bicarbonate  is  one  of  the 
most used carbonate because of high solubility, severe 
reaction  and  low  cost.
5  So,  excepients  such  as  water 
soluble  lubricants  (e.g.  PEG  4000,  6000  and  sodium 
benzoate),  sweeteners,  flavorings  and  water-soluble 
colors are applied.
5 
Polyvinylpyrolidone  (PVP)  is  an  effective  binder  of 
effervescent tablets. It can be added as dry powder or in 
a wet form as an aqueous or hydroalcoholic solution. 
Mannitol, PEG 6000 and water in small amounts can be 
used as effective binder.
5,6 
Low relative humidity (maximum of 25% or less) and 
moderate to cool temperatures (about 25 °C or 77 °F) 
in  the  environment  are  essential  to  prevent  sticking 
granule or tablets to tablet press machine.
5 
In producing direct compression method, the mixtures 
of  powder  with  excellent  flowability,  and  without 
particles segregation are needed and particle size of all 
raw materials should be equal. It is necessary to prepare 
granules, if particle size is small.
3,7 
In  fusion  method,  mostly  monohydrate  citric  acid, 
released  its  water  at  54  °C  in  order  to  obtain  the 
granules by agglomeration of the particles. Granulation 
with  nonreactive  solution  contain  of  ethanol  or 
isopropanol,  that  the  most  components  of  tablets  are 
insoluble  in  them.  So,  a  very  small  amount  of  water 
(0.1-0.5%) is active solution.
5  
Effervescent tablets are produced and controlled same 
as  conventional  tablets.  These  controls  are  included 
physicochemical  properties  such  as  hardness,  weight 
variation,  friability,  solution  time,  pH  and  content 
uniformity.
5 
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Purpose: The  aim of  this  study was  to design  and  formulation of  potassium  citrate 
effervescent tablet for reduction of calcium oxalate and urate kidney stones in patients 
suffering from kidney stones. Methods: In this study, 13 formulations were prepared 
from potassium citrate and effervescent base in different concentration. The flowability 
of powders and granules was studied. Then effervescent tablets were prepared by direct 
compression, fusion and wet granulation methods. The prepared tablets were evaluated 
for hardness, friability, effervescent time, pH, content uniformity. To amend taste of 
formulations,  different  flavoring  agents  were  used  and  then  panel  test  was  done  by 
using  Latin  Square  method  by  30  volunteers.  Results:  Formulations  obtained  from 
direct  compression  and  fusion  methods  had  good  flow  but  low  hardness.  Wet 
granulation  improves  flowability  and  other  physicochemical  properties  such  as 
acceptable  hardness,  effervescence  time  ≤3  minutes,  pH<6,  friability  <  1%,  water 
percentage < 0.5% and accurate content uniformity. In panel test, both of combination 
flavors;  (orange  -  lemon)  and  (strawberry  -  raspberry)  had  good  acceptability. 
Conclusion: The prepared tablets by wet granulation method using PVP solution had 
more tablet hardness. It is a reproducible process and suitable to produce granules that 
are compressed into effervescent tablets due to larger agglomerates. 
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Potassium citrate is very soluble in water and almost 
insoluble  in  alcohol  with  very  salty  taste.  Each  g  of 
potassium citrate (monohydrate) consists of about 9.3 
mmol of potassium and 3.08 mmol of citrate.
8 
Potassium citrate is used to replace sodium bicarbonate 
in  the  treatment  of  metabolic  acidosis  in  patients, 
alkalizing agent of urine and symptomatic relief of mild 
urinary tract infections. Studies were shown that it is 
effective  in  reduction  of  calcium  oxalate  and  urate 
kidney stones formation and prevent from bone loss.
9-12 
So,  studies  are  shown  that  oral  supplements  of 
potassium  prevents  hyperkalaemia  from  it  due  to  the 
high  absorption  from  the  gastrointestinal  tract  but 
slowly.
12 
Products  of  potassium  citrate  are  available  in 
pharmaceutical world market in the forms of: tablet (5, 
10,  and  15  mEq  potassium  citrate,  Urocit®-K), 
effervescent powder (1500  mg equivalent  to 13  mEq 
potassium  citrate,  Effercitrate®)  and  oral  solution.
8 
Although the mentioned dosage form are available in 
the  pharmaceutical  market,  none  of  them  are  held 
accountable  for  patient  requirement,  because  high 
doses of drug are needed for patients with calcium and 
urate kidney stones.  
These patients are using the drug into two forms: 1) a 
pharmaceutical dosage form with a low dose and high 
frequency  consumption  or  2)  the  bulk  of  the  raw 
materials. Until now in the pharmaceutical market, this 
potassium citrate effervescent tablet with 25 meq does 
not exist. It is a new and applications design. 
The  aim  of  this  study  is  design,  formulation  and 
preparation of the potassium citrate effervescent tablets 
containing  25  mEq  monohydrate  potassium  citrate. 
These  tablets  will  help  to  physicians  prescribing  and 
convenience  consumption  for  patients  suffering  from 
calcium oxalate and urate kidney stones. 
 
Materials and Methods 
Material 
Potassium citrate  (monohydrate),  sodium  bicarbonate, 
citric  acid  (monohydrate),  tartaric  acid,  PEG  6000, 
sodium benzoate, manitol, sorbitol and aspartame were 
procured by Merck (Darmstadt, Germany). Povidon k-
30  (PVP)  was  purchased  from  Rahavard  Tamin 
(Tehran,  Iran).  Orange  flavoring  agent  was  procured 
from Kagawa (China) and raspberry, strawberry, cherry 
and  lemon  flavoring  agents  were  prepared  by  Farabi 
pharmaceutical Company, (Isfahan, Iran). 
 
Preformulation 
Firstly,  the  formulas  were  made  up  in  the  different 
stoichiometric ratios from tartaric acid, citric acid and 
sodium  bicarbonate  based  on  below  reactions. 
According  to  Table  1,  materials  of  each  formulation 
were  weighed  and  then  2700  mg  of  monohydrate 
potassium  citrate  was  added  to  each  formulation. 
Finally,  after  preparation  of  appropriate  mixture,  the 
lubricants including 30 mg of PEG 6000 and 10 mg of 
sodium benzoate were added the mixture and then the 
tablets  compressed  by  using  a  single-punch  press 
machine (KILIAN & CO, Germany). For next stages, 
the  better  stoichiometric  ratios  were  selected  with 
regard  to  three  factors:  solubility,  effervescence  time 
and pH. 
 
H3C6H5O7.H2O+3NaHCO3           Na3C6H5O7+4H2O+3 CO2 
H2C4H4O6 + 2NaHCO3    Na2C4H4O6 + 2H2O + 2CO2 
 
Table 1. Composition of preliminary formulations (ratio) with their effervescence time, pH and solubility (Mean ± SD). 
Formulations  Tartaric acid  Citric acid  Na bicarbonate  Effervescent time(s)  pH  *Solubility 
S1  -  0.5  0.5  105 ± 2.08  5.9 ± 0.05  3 
S2  -  0.5  1  40 ± 1.52  6.2 ± 0.1  3 
S3  1  0.5  1  39 ± 1.51  6.1 ± 0.04  1 
S4  0.5  1  1  36 ± 2  6.1 ± 0.05  2 
S5  -  1  1  50 ± 2.13  5.9 ± 0.06  5 
S6  1  1  1  48 ± 2.01  6.1 ± 0.06  2 
S7  1.5  0.5  1  52 ± 1.8  6.1 ± 0.1  2 
S8  2  0  1  55 ± 1.83  6.1 ± 0.08  1 
S9  -  1  1.5  43 ± 1.51  6.1 ± 0.7  4 
S10  -  1  0.5  30 ± 3.11  5.6 ± 0.4  4 
S11  -  1.5  1.5  25 ± 2.13  5.6 ± 0.05  5 
S12  -  1.5  1  49 ± 1  5.6 ± 0.04  4 
S13  -  2  2  20 ± 2.07  5.5 ± 0.06  4 
*Solubility was defined by Likert Scale from 1= very poor, 2 = poor, 3 = average, 4 = good and 5 = excellent 
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Methods  of  Potassium  Citrate  Effervescent  Tablets 
Production 
Direct Compression 
According  to  Table  2,  raw  materials  of  each 
formulation  were  weighed  and  were  mixed  in  a 
tumbling cubic blender for 15 minutes.  
After the preparation of the primary powder mixtures, 
sweeteners including aspartame, sorbitol, mannitol and 
fruit  flavoring  agents  were  passed  through  the 
appropriate mesh and were added to the powders and 
these were mixed altogether for 5 minutes. Finally, the 
selective lubricants including sodium benzoate (10 mg) 
and PEG 6000 (30 mg) were added and again mixed for 
about 2-5 minutes with other material. 
Then,  the  powders  were  compressed  into  tablets  by 
using a single-punch press  machine (KILIAN &  CO, 
Germany),  with  25  mm  punch  set.  Weight  of  each 
tablet  was  considered  about  4.5  g.  At  the  end,  the 
tablets  were  dried  in  an  oven  with  air  circulation  at 
54°C for 1 hr and after cooling were packed in plastic 
tubes. 
 
Table  2.  Different  components  of  prepared  tablets  from  the 
direct compression (D) and fusion (f) methods. 
Ingredients (mg)  
Formulations 
F1  F2  F3  F4  F5  F6 
K citrate  2700  2700  2700  2700  2700  2700 
Citric acid  570  850  850  850  850  850 
Na bicarbonate  500  750  750  750  750  750 
Mannitol  -  -  60  120  -  60 
Sorbitol  -  -  -  -  60  - 
Aspartame  -  -  -  -  -  1.5 
 
Fusion Method 
According  to  the  formulations  which  are  shown  in 
Table  2,  amounts  of  citric  acid,  sodium  bicarbonate, 
potassium citrate and mannitol (sorbitol) were weighted 
accurately and were mixed for about 15 minutes in a 
tumbling  cubic  blender.  Then,  the  obtained  mixture 
was placed in an oven at 54 °C. The powder was mixed 
regularly  until  the  crystallization  water  of  citric  acid 
was  released  as  binder  factor  (approximately  30 
minutes).  After  obtaining  an  appropriate  pasty  mass, 
this wet mass was passed through sieve No. 20 and the 
obtained granules were dried in an oven at 54 °C for 1 
hr.  After  drying,  for  second  times  the  granules  were 
passed through sieve No. 20. 
In the next stage, sweeteners and flavors were added 
with the granule  mass and  mixed for  5 minutes  with 
other material. 
At last, the lubricants including sodium benzoate (10 
mg) and polyethylene glycol 6000 (30 mg) were added 
and  mixed  for  2-5  minutes  with  other  material.  The 
granule mixtures compressed into tablets by a single-
punch press machine (KILIAN & CO, Germany), with 
25 mm punch set. Finally, they were dried and packed 
with the previous methods. 
 
Wet granulation Method 
Wet  granulation  was  performed  on  F5  and  F6 
formulations. First, citric acid and sodium bicarbonate 
and potassium  citrate were  milled by  using miller  so 
that all powders were passed through sieve No. 35 and 
were  blended  for  10  minutes.  Then  9.5  %  w/v  PVP 
solution  in  absolute  ethanol  was  added  with  the 
mixture, so that white pasty mass was formed. This wet 
mass was passed through sieve No. 20 and the granules 
were dried in an oven at 54 °C for 75 minutes. So, the 
dried mass was passed through sieve No. 20 and the 
other  ingredients  were  added  to  them  like  as  fusion 
method.  The  granule  mixtures  were  compressed  into 
tablets by using a single-punch press machine (KILIAN 
&  CO,  Germany),  with  25  mm  punch  set.  Prepared 
tablets were dried in an oven with air circulation at 54 ° 
C for 90 minutes, then were wrapped in Aluminum foil 
and were packaged in plastic tubes. 
 
Precompression Tests 
Particle Size Analysis 
The  average  particle  size  of  powder  mixture  was 
determined  by  sieve  analysis  method.  100  grams  of 
powder  mixtures  and  granules  poured  on  the  upper 
sieve.  Series  of  sieve  were  placed  on  ERWEKA 
shaking apparatus for 10 minutes after this period; the 
amount remaining on each sieve was measured.
13 
The mean diameter of the powders was calculated by 
equation (1). 
? =  
𝑋𝑖?𝑖
100   Eq.1 
xi = The average size of both upper and lower sieve 
di = The percentage of the amount of i in limited area 
by two sieves.
  
 
Flowability 
For  evaluation  of  powder  flow,  the  angle  of  repose, 
compressibility index and Hausner´s ratio can be used. 
Angle of Repose (α): The powder or granule mass was 
passed  from  the  funnel.  Angle  of  repose  was 
determined by equation 2.  
The  average  of  three  measurements  was  interpreted 
according to USP NF. 2008.
14 
tan α  = 
𝐻?𝑖𝑔ℎ𝑡
0.5 Base   Eq. 2 
Height: The height of the formed cone  
Base: Diameter of the formed cone  
Compressibility  Index  and  Hausner´s  Ratio:  For 
measurement  of  bulk  density,  100  grams  of  powders 
and  granules  was  poured  into  the  graduated  cylinder 
(250  ml)  using  a  glass  funnel  and  its  volume  is 
recorded. 
ρ bulk = 
m
V bulk     Eq. 3  
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Tapping to  cylinder containing  the powder  continued 
until no further volume changes occur. Tapped density 
is obtained from the following equation. 
ρ tapped = 
m
V tapped       Eq. 4 
Compressibility Index and Hausner´s ratio parameters 
obtained  by  using  the  mean  of  three  measurements 
from ρbulk and ρtapped and were compared according to 
the USP NF.2008.
14 
Compressibility Index = 100  ×  
ρ tapped −ρ bulk
ρ tapped      Eq. 5 
Hausner´s Ratio =
ρ tapped  
ρ bulk    Eq. 6 
Post compression Tests 
Measurement of Tablet Hardness  
Hardness  of  tablets  was  determined  according  to  the 
USP  for  10  tablets  of  each  formulation  by  using  a 
hardness tester (Erweka, 24-TB, Germany).  
Hardness of effervescent tablets is usually lower than 
conventional  tablets  and  minimum  of  acceptable 
hardness of uncoated tablets is 40 N approximately.
1 
Measurement of Tablet Thickness  
The thickness of 10 tablets from each formulation was 
determined  by  using  calibrated  collies.  Average 
fluctuations of thickness, should not exceed more than 
5 % of its normal limits.
1 
Friability 
20 tablets of each formulation was taken randomly and 
after weighting altogether, were placed in the friabilator 
chamber (Erweka, TAP, Germany) for 4 minutes at 25 
rpm. If weight loss is greater than 1% is unacceptable.
1 
Evaluation of Weight Variation 
20  tablets  of  each  formulation  were  weighed 
individually and the mean of weight were determined. 
According to the USP for tablets with weight more than 
324 mg, among 20 tablets; just two tablets can be out 
of the 5% of the average weight and none deviated by 
more than twice that percentage.
14 
Measurement of Effervescence Time 
A single tablet was placed in a beaker containing 200 
ml of purified water at 20 °C ± 1 °C. Whenever a clear 
solution  without  particles  was  obtained  effervescence 
time has finished.
15 
The mean of three measurements of each formulation 
was reported.  
Determination of Effervescent Solution pH  
pH solution was determined with one tablet in 200 ml 
of  purified  water  at  20  ±  1  °C  by  using  pH  meter 
(Metrohm,  632,  Switzerland),  immediately  after 
completing the dissolution time.
15 This experiment was 
repeated 3 times for each formulation. 
Measurement of CO2 Content  
One effervescent tablet solved in 100 ml of 1N sulfuric 
acid solution and weight changes were determined after 
dissolution  end.  The  obtained  weight  difference  was 
shown  the  amount  (mg)  of  CO2  per  tablet.  The  CO2 
content reports are averages of 3 determinations.
15 
 
Evaluation of the Water Content  
10  tablets  of  each  formulation  were  dried  in  a 
desiccator containing of activated silica gel for 4 hours. 
Water content of 0.5% or less is acceptable.
15 
 
Assay 
The first, 3 effervescent tablets of potassium citrate was 
triturated and 347 mg of crushed powder (Equivalent to 
200  mg  of  anhydrous  potassium  citrate)  accurately 
weighed  and  was  dissolved  in  25  ml  of  acetic  acid 
glacial. Added 2 drops of crystal violet TS solution and 
titrated with 0.1N perchloric acid VS (USP) to a green 
end point. The same steps was done on a blank solution 
prepared from effervescent tablets of potassium citrate 
without active ingredient and was made any necessary 
correction.  In  the  titration,  the  prepared  blank  was 
consumed perchloric acid and corrected volumes were 
required. Each ml of 0.1N perchloric acid is equivalent 
to 10.21 mg of anhydrous potassium citrate.
 14 2700 mg 
of hydrated potassium citrate is equivalent to 2550.194 
anhydrous  potassium  citrate.  Of  course,  in  this  assay 
other  alternative  methods  such  as  atomic  absorption 
can also be used. 
N × V corrected by blank  =
mg
108.14   Eq.7 
N:  Normality  of  standardized  acid  by  potassium 
biphthalate according to USP 
mg: milligram of hydrated potassium citrate 
108.14: Eq of hydrated potassium citrate 
 
Evaluation of Content Uniformity  
10 tablets of each formulation were selected at random 
to measurement of the active ingredient amount. None 
of the tablets should not be out of range (90-110 %) of 
mention  amounts  in  formula,  and  coefficient  of 
variation (CV) should not be more than 6. If only one 
tablet was out of previous range and range of 80 – 120 
%, 20 tablets must be tested. Among these 20 tablets, 
anything  of  them  should  not  be  out  of  range  90-110 
percent.
14 
 
Determination of the Equilibrium Moisture Content  
Three  desiccators  were  prepared  containing  saturated 
salt  solutions  of  potassium  nitrate  (for  creation  90% 
RH, at 18 °C), sodium chloride (for creation 71% RH, 
at 18 °C) and sodium nitrite (for creation 60% RH, at 
18 °C). Three tablets of each formulation were placed 
in desiccators. Then, the equilibrium moisture content 
was  determined  by  Karl  Fischer  method  and  the 
autotitrator  device  (Mettler,  TOLEDO-DL53, 
Switzerland) in the first day and after 7 day.
14 
 
Evaluation of Prepared Tablets Taste 
Before  beginning  the  evaluation,  the  taste  ability  of 
volunteers  was  measured  by  four  base  tastes  (salt,  
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sweet, sour, bitter) by 20 ml of 0.2% sodium chloride, 
2% sucrose, 0.07% citric acid, and 0.07% caffeine in 
water respectively.
16 
To  evaluate  the  taste,  panel  tests  were  performed  by 
Latin  Square  method.  The  first,  with  the  help  of  5 
volunteers,  7  flavors  which  were  added  to  F6 
formulation  (optimum  formulation),  were  examined 
(Table  3).  Thus,  the  volunteers  were  asked  to  score 
each of the formulation from 1 = very bad, 2 = bad, 3 = 
no  taste,  4  =  good  and  5  =  excellent  taste  based  on 
Likert Scale. 
At next stage, another 30 volunteers were asked to give 
points to the 2 selected flavors of early stages from 1 = 
very  bad,  2  =  bad,  3  =  no  taste,  4  =  good  and  5  = 
excellent taste based on Likert Scale. 
 
Table 3. Different flavors were used for panel test of potassium 
citrate effervescent tablets. 
Code  Flavoring agent  Amount (mg) 
A  Raspberry  4.4 
B  Strawberry  4.4 
C  Cherry  4.4 
D  Orange  4.4 
E  Lemon  8.8 
F  Orange & Lemon  4.4 & 8.8 
G  Raspberry & strawberry  4.4 & 4.4 
 
In all time of experiments, the standard conditions of 
panel test were considered such as temperature equal to 
21°C, 20 minutes distance from the previous samples, 
samples with similar concentrations of drugs and have 
been done without exchanging the volunteers' idea.
16 
 
Results  
Results  of  preformulation  study  is  shown  that 
formulations with stoichiometric ratios 1:1 and 1.5:1.5 
(S5,  S11)  were  selected  as  the  appropriate  base 
formulations  in  tableting  process,  and  with  better 
physicochemical characteristics. 
Results  from  characterization  of  the  powder 
formulations containing of the particle size distribution, 
angle  of  repose,  compressibility  index  and  Hausner´s 
ratio are given in the Tables 4, 5 and Figure 1.  
The  results  of  obtained  from  tablets  evaluation  are 
presented  for  hardness,  friability,  tablet  thickness, 
effervescence  time,  pH,  weight  variation,  water  and 
CO2  content,  content  uniformity  and  equilibrium 
moisture  content  properties  are  given  in  the  Tables 
5,6,8, too.  
The  particle  size  distribution  of  three  manufacturing 
methods  is  listed  in  Tables  4  and  5.  The  mean 
diameters of granules were greater than the powders. 
Figure 1 shows the particle size distribution diagram of 
F5 formulation which has normal distribution. 
 
 
Table 4. The mean diameter, particle size distribution and percentage on each sieve of the obtained formulations from direct 
compression (D) and fusion (f) methods. 
Formulations 
Sieve number 
Mean diameter(μ) 
<20  20-25  25-30  30-35  35-40  40-70  70-100  >100 
D1  1.69  1.46  5.64  5.29  1.62  47.9  16.13  20.28  311.42 
f1  2.59  3.08  8.06  5.74  1.25  48.41  12.73  18.15  340.63 
D2  1.9  2.73  6.62  6.66  1.28  45.42  16.1  19.29  326.08 
f2  2.33  2.17  6.57  6.62  1.44  67.74  7.08  6.05  360.47 
D3  1.52  2.01  4.59  5.67  1.17  48.04  13.63  23.38  307.95 
f3  3.05  3.47  7.69  7.91  1.92  55.45  12.41  8.09  367.03 
D4  1.8  2.09  5.25  4.52  1.6  44.47  13.85  26.42  304.59 
f4  7.02  4.31  7.39  6.64  0.62  51.63  8.76  13.62  381.84 
D5  1.84  2.24  3.06  6.56  12.55  50.86  12.51  10.38  347.48 
f5  3.02  2.74  3.9  6.26  12.94  57.55  8.08  5.51  373.05 
D6  1.41  2.06  4.5  4.43  1.77  44.66  16.36  24.82  299.12 
f6  8.53  3.07  6.33  5.04  0.75  44.93  13.36  17.98  363.39 
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Table 5. Particle size distribution, mean diameter and flowability of obtained granules in wet granulation method together with tablets 
characteristics for G5 and G6 formulations. 
Formulations  -  G5  G6 
Sieve number 
<16  0.28  0.04 
16-20  2.26  2.68 
20-25  7.73  21.17 
25-30  11.09  33 
30-35  16.08  6.74 
35-40  22  0.51 
40-70  33.66  30.33 
>70  6.9  5.52 
Mean diameter (μ)  471.2  556.71 
Flow Properties 
Hausner´s ratio  1.06±0.01  1.08±0.02 
Compressibility index  5.73±0.66  7.6±2.14 
Angle of repose  15.076±0.12  14.713±0.59 
Tablets characteristics 
Weight variation  4.401 ± 0.113  4.416 ± 0.063 
Hardness  78.85 ± 2.26  65.05 ± 2.72 
Content uniformity, (%CV)  2744 ± 97.5 (3.55)  2742 ± 54.9 (2.0) 
Water content  0.0405 ± 0.01  0.0096 ± 0.005 
Tablet thickness  5.97 ± 0.06  6.048 ± 0.06 
Effervescence time(s)  132 ± 2  112.7 ± 2.52 
pH solution  5.8 ± 0.02  5.8 ± 0.02 
CO2 content  313 ± 13  423 ± 16 
Assay (mg)  2700 ± 40  2720 ± 20 
Friability (%)  0.973±0.02  0.936±0.05 
 
 
 
Figure  1.  Particle  size  distribution  diagram  of  F5  in  direct 
compression (D), fusion (f) and wet granulation (G) methods 
 
According to the results in Table 7, PVP 0.5 % (w/w) 
and sieve No. 20 were chosen considering hardness and 
effervescence time. 
 
Range of  hardness  in  obtained formulations  of  direct 
compression method (D) was varied from 15 N to 22 N 
and obtained granules from the fusion method (f) were 
shown a slight increase from 20 - 25 N (Table 6).   
Produced  tablets  were  evaluated  by  hardness,  weight 
variation, tablet thickness, friability, effervescent time, 
pH, content uniformity, water and CO2 content. These 
values are reported in Table 5. In Table 5, hardness was 
shown threefold increase in wet granulation method. 
In this study, at 60 % RH and 18°C, the variation in 
percentage of equilibrium moisture content after 7 days 
was nothing, but, at 90 % RH and 18°C, it was most. 
For correcting the potassium citrate effervescent tablet 
tastes, in the first stage, volunteers selected orange – 
lemon and strawberry - raspberry flavors. Figure 2 is 
shown means of obtained results from the 30 volunteers 
in  the  panel  test  by  Latin  Square  method.  Both  of 
desirable flavors had good acceptability. 
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Figure 2. Evaluation of prepared tablets taste by Latin Square 
method. 
 
 
 
Discussion 
The pharmaceuticals which are suitable for formulation 
of  the  effervescent  tablets  should  have  specific 
particulars  such  as  quick  absorption  of  drug,  good 
dissolution in water and high dose.
17 These particulars 
were existed in potassium citrate. 
Potassium  citrate  recommended  for  the  people  who 
suffer from urate and calcium kidney stones. One study 
which was done on 500 patients with recurrent kidney 
stones showed potassium citrate have been reduced the 
prevalence  of  kidney  stones  from  two  stone  to  half 
stone in a year.
8 Also, these patients need to consume 
large  amount  of  water  daily,  thus,  solution  of 
effervescent tablet in the water could remove this need. 
Currently,  patients  are  taking  potassium  citrate  into 
form of raw material powder. This kind of usage is not 
desirable  for  flavor  and  is  not  the  exact  for  the 
consumption dosage. Therefore, the main objective of 
this  study  is  design  and  formulation  of  potassium 
citrate effervescent tablets which have good taste and 
also have certain dosage. The main uses of these tablets 
are  reduction  of  calcium  oxalete  and  urate  stones  in 
patients with kidney stones. 
Table 6. Flowability properties and hardness of tablets obtained from direct compression (D) and fusion (f) methods (Mean ± SD). 
Flowability properties 
Formulations 
F1  F2  F3  F4  F5  F6 
Angle of repose (D)  27.42±1.06  29.9±0.75  26.7±0.02  26.06±0.85  27.05±0.0  26.38±1.37 
Angle of repose (f)  24.03±1.17  25.17±1.13  24.48±1.33  24.12±1.73  26.06±0.99  24.9±1.76 
Hausner´s ratio(D)  1.103±0.06  1.142±0.0  1.099±0.01  1.087±0.01  1.13±0.01  1.12±0.0 
Hausner´s ratio (f)  1.083±0.01  1.095±0.01  1.073±0.01  1.066±0.0  1.083±0.01  1.08±0.01 
Compressibility index (D)  9.33±1.94  12.48±0.64  9.08±1.33  7.99±0.66  11.50±1.02  11.07±0.65 
Compressibility index (f)  8±0.78  8.75±1.26  6.813±0.75  6.2±0.62  7.677±0.7  7.437±0.64 
Hardness (Newton) (D)  15±2.34  17±3.54  17±3.96  17.5±5.11  22±4.26  17.5±5.16 
Hardness (Newton) (f)  20±4.81  20±5.21  20±2.85  23±3.49  25±6.53  22±4.73 
 
 
Table 7. Relationships between (%PVP /tablet, Sieve No) and (hardness, effervescence time) in formulation G6 (Mean ± SD). 
Independent properties   Dependent properties  
PVP (% W/W) /tablet  Sieve No.  Hardness (N)  Effervescence time (s) 
0.34  20  52.9±6.5  125±1.11 
0.36  20  55.5±4.81  138±1.52 
0.43  40  68.25±5.49  180±1.83 
0.43  20  68.75±3.51  162±1.74 
0.45  16&20  53.5±4.16  140±2.21 
0.45  20&25  36.66±2.32  130±1 
0.5  20  66.75±2.12  170±2.03 
0.67  16&20  112.4±3.95  187±0.57 
1  20  90.83±4.45  240±1.51 
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Table 8. Equilibrium Moisture Content (%) in the G5 and G6 effervescent tablets (Mean ± SD). 
Microclimates 
G5  G6 
1st Day  7th Day  Variation  1st Day  7th Day  Variation 
60% RH, 18°C  11.31±0.96  11.42±0.77  0.10  10.02±0.46  10.13±0.74  0.11 
71% RH, 18°C  11.81±0.47  14.86±0.51  3.05  10.64±0.84  13.51±1.43  2.88 
90% RH,18°C  12.09±1.1  22.39±0.96  10.30  11.28±0.61  14.44±0.82  3.15 
 
Ratios of effervescent components in the formulations 
of S5 and S11 were led to better solubility, pH less than 
6, and an appropriate effervescent reaction. In the next 
steps,  this  stoichiometric  ratios  were  used  for  the 
preparation  of  effervescent  tablets  (Table  1).  In 
comparison  of  formulations  containing  tartaric  acid, 
this  result  was  obtained:  tartaric  acid  should  remove 
from  the  formulations  because  of  low  solubility  and 
much precipitation. 
The mean diameter of particles in the wet granulation 
method  is  larger  than  the  average  diameter  of  the 
particles in the two other methods due to the adhesion 
of  smaller  particles  and  formation  of  larger  particles 
(Tables 4 and 5).  
Accordingly to Figure 1, diagram peak of f5 is drawn 
upward  and  is  drawn  to  the  right  for  G5  which  is 
representative of particle size increase in granulation. 
Angle of repose is lessened in the produced granules 
due  to  shape  changing  into  sphere  and  contact  level 
deduction. 
As results showed, angle of repose reduced in fusion 
and wet granulation methods. For example, angles of 
repose  of  D6,  f6,  G6  (the  same  formulations,  but 
different manufacturing methods) report: 26.38, 24.496 
and 14.713, respectively (Tables 5 and 6). Hausner´s 
ratio and compressibility  index are  reduced in  fusion 
and  wet  granulation  methods.  Granulation  (fusion  or 
wet)  increases  flowability  and  decreases  angle  of 
repose  due  to  increasing  of  particle  size  and  shape 
changing into sphere, but these changes are higher in 
the  wet  granulation.  In  other  study,  the  results  were 
extracted similar to our results.
18 
Tablets'  hardness  of  D5,  f5  and  G5  (the  same 
formulations  but  different  manufacturing  methods) 
were 22, 25, and 78.85 respectively. Wet granulation 
improves  hardness  of  tablet  due  to  internal  porosity 
granules  and  the  plastic  deformation.
18  Also,  for 
hardness  increasing,  the  dry  forms  of  binder  such  as 
mannitol , sorbitol and PVP were used, but, the desired 
results were not found. Then wet granulation method 
using PVP was performed on the best formulations (G5 
and  G6).These  formulations  were  better  because  of 
flowability and they had not capping and sticking in the 
manufacturing process. Increasing PVP percentage was 
found to enhance the hardness and effervescence time 
(Table  7).  In  the  other  study  was  shown  that  wet 
granulation  technique  could  improve  compressibility 
and flowability properties and hardness that the results 
were in agreement with this study.
15 
Thickness of the tablets must be between 6.1 ± 0.3 mm, 
that  the  results  are  acceptable  regarding  to 
pharmacopoeia standards (USP NF.2008). 
According to the USP, in the tablets which their weight 
are more than 324 mg, among 20 tablets, just 2 tablets 
can be exceed from ± 5 % of the weight average (for G5 
±  221.14  and  for  G6  ±  221.21)  that  the  result  are 
acceptable.
14 
pH less than 6 is necessary to increase the absorption of 
effervescent  tablets,  that  pH  of  two  optimum 
formulations is less than 6. The equal pHs in different 
samples  of  one  formulation  indicate  that  granule 
mixtures  are  uniform.  In  other  study  on  effervescent 
granules containing citric acid and sodium bicarbonate 
has  been  done,  solution  pH  which  is  obtained  from 
dissolving  granules  was  measured  at  5.64.  It  is 
comparable with the results in this study.
15 
Effervescence  time  of  tablet  must  be  less  than  3 
minutes that the results are indicated this subject.
15 
In the studied formulations, CO2 contents of G5 and G6 
were 313 and 423 mg, respectively. One study has been 
shown  that  amount  of  carbon  dioxide  in  2.5  g 
effervescent tablets containing of aspirin (prepared by 
direct compression method) were measured at 242 mg
19 
and other study reported that in each grams of formulas 
containing of citric acid and sodium bicarbonate CO2 
content  was  292  mg  which  is  comparable  with  the 
results.
15 In the formulation G5, lower level of CO2 was 
obtained. In this formulation, sorbitol exists which is a 
hygroscopic  matter.  Absorbed  moisture  by  sorbitol 
causes  beginning  of  an  effervescent  reaction  in  the 
small scale. 
As  Table  5  shows,  the  friability  of  tablets  was 
satisfactory, attributed by the acceptable hardness. 
In the formulation G5 and G6, water content was gained 
0.0405  and  0.0096,  respectively.  Reason  of  higher 
water  content  in  formulation  G5  is  the  presence  of 
sorbitol and the absorption of moisture. The prepared 
tablets  by  the  wet  granulation  have  very  low  water 
content due to getting temperate during drying process. 
Effervescent materials are hygroscope highly and they 
are  susceptible  for  degradation  by  air  humidity.  Of 
course  potassium  citrate  is  a  hygroscopic  substance 
since  potassium  citrate  effervescent  tablets  are 
containing  large  amounts  of  active  ingredient;  much 
ability  will  have  to  absorb  moisture.  Consequently, 
possibility  of  effervescent  reaction  beginning  and 
instability is high in these tablets. So it is necessary to 
determined  that  the  provided  tablets  are  stable  up  to  
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what  moisture  percent.  At  60  %  RH  and  18°C,  the 
variation  in  percentage  of  equilibrium  moisture  content 
after  7  days  was  alittle,  thus,  the  granules  ready  to  be 
compressed into tablets aren't hygroscopic mostly up to 60 
% RH at 18°C. Also G5 formulation equilibrium moisture 
content after 7 days showed more variation because the 
presence of sorbitol that is a hygroscopic substance. 
Since,  the  amount  of  active  ingredient  (hydrated 
potassium citrate) can fluctuate in ranges from 2430 to 
2970 mg and coefficient of variation percents (CV %) 
were not upper than 6%, content uniformity of G5 and 
G6 were in the acceptable range and the prepared tablets 
have USP standard about amount of active ingredient 
and the content uniformity. 
As depicted in Figure 2, volunteer gave more scores to 
both  the  combination  flavor  of  orange-lemon  and 
raspberry-strawberry.  Strawberry-raspberry  flavors 
took more scores compare to orange–lemon but closed 
results  showed,  selection  of  flavor  is  depending  on 
individual relish. 
 
Conclusion 
In this work, it was tried to produce potassium citrate 
effervescent tablets by using direct compression, fusion 
and  wet  granulation  techniques.  The  results  of  this 
study show that wet granulation is a suitable method to 
produce effervescent tablets of potassium citrate due to 
the  large  size  of  these  tablets  in  the  pharmaceutical 
industry. Wet granulation is one of the most common 
methods  used  for  granulation  in  the  industry.  This 
method  is  obtained  by  adding  a  solution  with  (or 
without) adhesive to the powder to form a wet mass. In 
this study, the prepared tablets were acceptable under 
the terms of pharmacopoeia standards only when PVP 
was added as a binder during the granulation process. 
Due to particle adhesion, the prepared tablets through 
wet granulation technique had better compression and 
uniformity. They had not processing problems such as 
sticking, capping, and friction.  
Among the studied formulations, only the formulation 
G6 was desirable for all physiochemical characteristics, 
including effervescent time under 3 minutes or less, pH 
<6,  friability  under  1  percentage,  the  water  content 
below 0.5 percentage, low weight variation, and correct 
content uniformity. Finally, its taste was also amended 
by adding strawberry - raspberry flavor. 
These tablets will help to convenience consumption of 
potassium citrate and more acceptances of patients who 
are affected by urate and calcium kidney stones.  
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